Although Post-Authorisation Safety Studies (PASS) have been around since 2001, most regulatory writers would have been unaware of their existence until the recent changes in European regulations, which include mention of these studies as part of general strengthening of pharmacovigilance procedures. Interventional PASS will largely adhere to International Conference on Harmonisation requirements, but non-interventional (NI) PASS should be reported according to a particular mandated format, which may appear strange to writers used to drafting clinical study reports for interventional trials. Given their novelty, there is no consensus as to how these reports should be drafted. This article addresses the structure of NI-PASS reports and provides an interpretation, albeit preliminary, of the corresponding European Medicines Agency guidance text.
Editor-in-Chief
Co-Editors
Managing Editor
Victoria White
Deputy Managing Editor
Alicia Brooks Waltman
Associate Editors
Section Editors
AI/Automation
Biotechnology
Digital Communication
EMWA News
Gained in Translation
Getting Your Foot in the Door
Good Writing Practice
In the Bookstores
Publications
Medical Communications/Writing for Patients
Medical Devices
My First Medical Writing
News from the EMA
Freelancing
Pharmacovigilance
Regulatory Matters
Regulatory Public Disclosure
Teaching Medical Writing
Louisa Ludwig-Begall / Sarah Kabani
The Crofter: Sustainable Communications
Veterinary Writing
Editors Emeritus
Layout Designer
Chris Monk